Medical device company Globus Medical (NYSE: GMED) will be reporting results this Tuesday after market close. Here’s what to expect.

Globus Medical beat analysts’ revenue expectations last quarter, reporting revenues of $769 million, up 22.9% year on year. It was an exceptional quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates.

Is Globus Medical a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Globus Medical’s revenue to grow 21.8% year on year, improving from the 6.6% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Globus Medical rarely misses Wall Street’s revenue estimates.

Looking at Globus Medical’s peers in the medical devices & supplies - specialty segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Haemonetics’s revenues decreased 2.7% year on year, beating analysts’ expectations by 2.4%, and Bausch + Lomb reported revenues up 9.8%, topping estimates by 1.5%. Haemonetics traded down 10% following the results while Bausch + Lomb’s stock price was unchanged.

Read our full analysis of Haemonetics’s results here and Bausch + Lomb’s results here.

The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the medical devices & supplies - specialty stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.4% on average over the last month. Globus Medical is down 2.6% during the same time and is heading into earnings with an average analyst price target of $107.17 (compared to the current share price of $90.06).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.